Nordion divests MDS Nordion
Nordion has signed a non-binding letter of agreement with Best Medical International for the divestiture of MDS Nordion.

The MDS Nordion operations currently support four lines of business out of the Fleurus, Belgium location:
  • Agiris: Non-destructive testing equipment and sources;
  • Glucotrace: FDG imaging agent; 
  • TheraSphere: Targeted liver cancer radiotherapeutic; and
  • Radiochemical business: Generic cyclotron and reactor isotopes.

The letter of agreement for the divestiture will include three lines of business and exclude the TheraSphere business which will be retained by Nordion, said the company.